EURAX ® Crotamitone

EURAX ® is a Crotamitone based drug

THERAPEUTIC GROUP: Antipruriginosi including antihistamines, anesthetics, etc.

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications EURAX ® Crotamitone

EURAX ® is indicated in itchy skin manifestations associated with different states and in the treatment of scabies infestation.

Mechanism of action EURAX ® Crotamitone

EURAX ® is a drug based on Cotramitone, the active ingredient used effectively in the treatment of skin itching and scabies mite infestations.

Despite a well-characterized clinical efficacy, its mechanism of action is still unclear, evidently linked to its chemical-physical properties, most likely responsible for a cooling and soothing action on the skin subjected to irritation as well as anticinetic to the skin. scabies mite.

The aforementioned characteristics carry out an antipruritic and acaricidal action, supported by advantageous pharmacokinetic properties which allow the modestly systemically absorbed quota, following topical application, to be rapidly eliminated without overloading the hepatic metabolism.

However, direct bacteriostatic properties against Staphylococci and Streptococci are still unclear.

Studies carried out and clinical efficacy

CROTAMITONE AND IVERMECTIN IN THE TREATMENT OF THE SCAND

Cutan Ocul Toxicol. 2013 Feb 25. [Epub ahead of print]

Interesting study that demonstrates how Crotamitone can be as effective as Ivermectin in the treatment of Scabies, although there are some stages of the biological cycle of the parasite that are naturally resistant to therapy.

CROTAMITONE AND ITCHING CONTROL

Exp Dermatol. 2012 Mar; 21 (3): 201-4. doi: 10.1111 / j.1600-0625.2011.01433.x.

Work demonstrating the effectiveness of Crotamitone in reducing itching induced by various pruritic elements such as histamine, substance P and PAR2 receptor agonists, thus highlighting the extensive clinical efficacy of the active ingredient.

CLINICAL EFFECTIVENESS OF CROTAMITONE

J Clin Aesthet Dermatol. 2009 Jan; 2 (1): 20-5.

Case report that demonstrates the clinical efficacy of Crotamitone in guaranteeing a remission of the symptomatology present in the course of rosacea and seborrheic dermatitis, against an excellent tolerability.

Method of use and dosage

EURAX ®

Cream for cutaneous use of 10 g of Crotamitone per 100 g of product.

Generally in case of itching it is suggested to apply the appropriate amount of cream on the affected region 2-3 times a day taking care to lightly rub the skin, prolonging the therapy for a few days beyond the disappearance of symptoms.

In the case of scabies instead it is suggested to apply the cream on dry skin after a warm bath, once a day, preferably in the evening, taking care to extend the application to the regions most affected by the infestation such as interdigital spaces, wrists, armpits and genital organs.

Warnings EURAX ® Crotamitone

EURAX ® therapy should be preceded by an appropriate medical consultation to clarify the origin of the symptoms.

If the treatment had no effect after 5 days or caused the onset of side effects, it would be advisable to consult your doctor with whom to evaluate the possibility of suspending or varying the therapy.

EURAX ® is a topical drug, therefore it should not be applied to the exposed mucous membranes and conjunctiva.

Keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

The absence of studies able to better characterize the safety profile of Crotamitone for fetal and infant health limit the use of EURAX ® during pregnancy and in the subsequent period of breastfeeding exclusively to cases of real need and always under strict medical supervision.

Interactions

No clinically relevant drug interactions are currently known.

Contraindications EURAX ® Crotamitone

The use of EURAX ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients, or with particularly striking skin disorders.